SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing extreme volatility following its massive IPO as investors debate the impact of the newly announced $60 billion all-stock acquisition of AI startup Cursor. Community discussion remains polarized, with bulls betting on aggressive growth and Elon Musk's long-term vision, while skeptics are pointing to significant dilution concerns, the lack of current profitability, and a tight initial float that has created a hot-potato environment.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is seeing intense community speculation as investors debate the impact of its recent workforce realignment and new AI compute agreement with AMD. While some participants are optimistic about a potential re-rating driven by AI growth and cost-saving measures, others are cautious, actively discussing the possibility of a share offering and the impact of the company's debt levels on future performance.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is facing intense downward pressure and widespread investor skepticism following earnings that fell short of analyst expectations, sparking intense debate over the company's long-term viability and potential for bankruptcy. While some bargain hunters see a potential recovery play or buyout candidate given the heavily shorted interest, others remain deeply bearish, citing failing foot traffic, poor management execution, and an unsustainable debt load as reasons to avoid the stock.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is under heavy community scrutiny as investors brace for the final data readout from its Phase 3 REGAL trial, with intense debate centered on the upcoming vote for a 20 million share RSU expansion. While bulls argue that the extended trial duration and recent protocol adjustments indicate strong patient survival and a potentially curative treatment for AML, bears and skeptics are voicing significant concerns regarding potential shareholder dilution and the historical failure of similar cancer vaccine programs.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing significant momentum alongside broader memory and storage sector leaders, driven by intense institutional demand for data center infrastructure and artificial intelligence workloads. The community remains highly active, debating the sustainability of these record-breaking valuation re-ratings and the potential for a long-term cyclical supercycle versus concerns of a temporary bubble.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing massive investor enthusiasm following a strong earnings report that highlighted record bookings, high gross margins, and growth in its edge computing and defense pipelines. The community is actively discussing the stock's low float and the potential for a significant re-rating as institutional interest grows and investors wait for upcoming military contract announcements.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is trending as investors capitalize on its role as a strategic domestic supplier for high-growth sectors like defense, AI data-center optics, and LEO satellite infrastructure. The community is heavily focused on the company's scaling production capacity, potential for future contract awards within the Anduril-led defense ecosystem, and the low-float nature of the stock, which has led to intense speculation about long-term upside potential and volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to Hantavirus outbreak concerns, with community discussion centered on the company's mRNA platform potential and the volatility often associated with pandemic-related trading. Market participants are actively debating the sustainability of the recent upward momentum while closely monitoring new health updates and institutional accumulation patterns.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is generating significant buzz following strong Q1 results, a raised revenue outlook, and a new $250 million share buyback program. The community is actively debating the stock's potential for a short squeeze against its depressed valuation, while simultaneously highlighting long-term optimism surrounding its pivot into robotics and expansion in the autonomous robotaxi sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors brace for pivotal 52-week data, with the community actively speculating on a potential buyout as trial milestones align with upcoming investor conferences. Investors are closely monitoring clinical trial updates and corporate signaling, viewing the current period as a strategic 'watch and wait' phase before a anticipated catalyst-driven repricing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.8%  - Here's Why

Incannex Healthcare (NASDAQ:IXHL) Shares Up 2.8% - What's Next...

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Equity

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

Incannex Healthcare Stock Falls 35% Over Announcement Of IHL-42X Development Plan, Stock Offering

(RTTNews) - Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its...

Why Did IXHL Stock Slump 35% Today?

The company priced its private placement at $5 per share, below its previous closing price of $5.97, and said the proceeds would be used for its Phase 3 treatment for sleep apnea, which is expected to begin in the second half of 2027.

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 842,808 shares, a drop of...

Incannex Healthcare (NASDAQ:IXHL) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Incannex Healthcare to a "sell" rating in a report on Saturday...

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - Here's Why...

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 21,688,567...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Current Price	$3.67
Prev Close	$3.83
Open	$3.90
Dividend Yield	0.00%
50-Day Moving Average	$3.72
Beta	-0.71
Avg. Volume	256,566.38
PE Ratio	-0.21

52-Week High	$49.80
52-Week Low	$2.49
Market Capitalization	$43.91M
EPS (Annual)	-$40.82
Price to Book	0.67
Revenue Per Employee	$7,166.67

IXHLIncannex Healthcare Limited - ADR

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News